Treatment Considerations Based Upon the Best Available Evidence Research Results

 

Dr. FLEMING:  https://www.flemingmethod.com/best-available-published-evidence

 

1.  Treatments to Consider Based Upon the Best Available Evidence Research Results

 

This pdf contains Treatments for you and your physician or healthcare provider to consider based upon the Best Available Research Results. 

 

2.  No Symptoms

​

3.  Phase I Mild Symptoms

​

4.  Outpatient SARS-CoV-2 Infection

​

5.  Inpatient InflammoThrombotic Response (ITR) COVID-19

​

6.  Combined Outpatient Infection & Inpatient COVID-19 (costs)

​

7.  Combined Outpatient Infection & Inpatient COVID-19

​

8.  Vaccine Adverse Events & Shedding

 

5 June 2021

Treatments to Consider Based Upon

the Best Available Evidence Research Results.

 

PROPOSED TREATMENT APPROACHES FOR PROPHYLAXIS, SARS-COV-2, COVID-19, AND POST-VACCINATION; FOR YOU TO DISCUSS WITH YOUR PHYSICIAN. THIS IS NOT A SERVICE, THE SALE, BUYING, OR MARKETING OF A PRODUCT, OR THE PRACTICING OF MEDICINE.

 

This document has been assembled following repeated requests for such information. Given the discordant dissemination of information and misinformation, it is clear that clinicians are receiving little guidance in the treatment of individuals infected with SARS-CoV-2; who have developed the InflammoThrombotic Response (ITR) disease of COVID-19; or who have undergone injection of a vaccine containing genetic material encoding the gain-of-function spike protein.

Consequently, pursuant to those requests, and the need to provide some level of guidance, I have assembled based upon the best available evidence research results, the following proposed treatment options to be considered by your doctor to address these various health problems and concerns (This does not represent a “service.”)

Also included are potential options for treatment of Individuals infected with SARS-CoV-2 or have been injected with SARS-CoV-2 Vaccines, based upon mechanisms of action and the best available evidence research results.

These best available evidence research results and understood mechanisms of action are to be followed only under the care and supervision of your physician.

Nothing within this material should be considered as my providing you with medical care, a service, sale or advertisement of a product or medical advice.

I have no relationship to any of the companies that make any of  these drug products.

Any care or treatment provided to you is the responsibility of your personal physician, as well as yourself, and should follow informed consent. There is no expressed U.S. Constitutional authority under Article I or II, for the Federal Government to direct, govern, or otherwise be involved in your personal Health Care. https://constitutioncenter.org/interactiveconstitution/full-text

The fundamental expressed concerns people appear to have as a result of becoming infected with SARS-CoV-2 or having been vaccinated include:

(1)    The possible insertion of the genetic code sequence(s) found within the Drug Vaccines through Reverse Transcription (RT) into human DNA, potentially made possible as a result of either the RT capacities present within the SARS-CoV-2 virus itself (spike protein, nucleocapsid, envelope, or other genetic sequences); the Long Interspersed Nuclear Elements (LINE-1) found within approximately 18% of the human genome; or RT facilitated in CD-4 cells and platelets as previously demonstrated with Human Immunodeficiency Viruses (HIV); raise increased concerns about the potential of genetic material being inserted into the human genome, or replacing components of the human genome; particularly when coupled with Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR).

(2)    The circulation of the spike protein within the body, from the virus or drug vaccine with induced production of SARS-CoV-2 spike proteins, as well as other genetic material; needs to be neutralized to reduce the dissemination of this genetic material as well as prion-like domains found near the receptor binding domain (RBD) of the spike protein; either within the individual infected or injected, to minimize the InflammoThrombotic Response (ITR) resulting in the disease COVID-19; the potential development of amyloidal and prion diseases, occurring within the brain resulting from the prion-like domain at the Receptor Binding Site (RBS) of the spike protein as seen in animal models; and to minimize the shedding of this genetic and protein material that could be transmitted to others, resulting in further disease.

(3)    The need to reduce, inhibit or prevent the viral or other non-native individual genetic material from being re-expressed at a later time – as seen with many viral diseases – through transcription and translation of viral or genetic material inserted into the human DNA through the above noted RT process, and

(4)    The immediate and long treatment of potentially damaged human DNA, including but not limited to the potential short and long-term neurologic, cardiac, and prionlike diseases and sequela.

 

OVERVIEW OF THE SARS-CoV-2 PROCESS IN INFECTED AND VACCINATED

 PEOPLE INCLUDING THE INFLAMMOTHROMBOTIC RESPONSE (ITR) 

DISEASE COVID-19. https://www.flemingmethod.com/documentation

 

1.  Treatments to Consider Based Upon the Best Available Evidence Research Results

 

CURRENTLY SUGGESTED TREATMENTS BASED UPON BEST AVAILABLE EVIDENCE RESEARCH RESULTS PROPHYLAXIS FOR PEOPLE CONCERNED ABOUT SARS-CoV-2

As someone who has practiced clinically I am not a believer in the use of medications for prophylaxis when there is no disease yet to be treated. Just as treating an abnormal blood test without the presence of a disease to be treated makes it impossible to measure a treatment benefit – given no disease to measure – or treatment failure; the only potential measureable outcome is that of potential risks or complications resulting from the treatment. E.g. prophylaxis of cancer by having chemotherapy when there is no measureable evidence of cancer.

That being said, the following steps based upon best available evidence research results have been shown to reduce the development and progression of InflammoThrombotic Response (ITR) Diseases; including but not limited to aging, coronary artery disease, cancer, strokes, hypertension, diabetes, and obesity.

Modification of diet and lifestyle, to reduce risk factors for these chronic inflammatory diseases, as I and others have previously published and discussed [https://www.youtube.com/watch?v=OE6cnZFOBJ8] have been shown to reduce the risk of associated comorbidities associated with SARS-CoV-2 & COVID-19.

In addition, it has been the standard of care, that patients with respiratory problems, particularly those with compromised airway flow and reductions in acceptable oxygen levels within the arteries (viz. oxygen saturation), have received bronchodilator treatments and steroids when deemed medically appropriate.

Many researchers and clinicians would additionally advocate for sufficient dietary supplementation of vitamins and minerals to maximize overall immune response – particularly under “stressful” conditions.

Examples of these best available evidence research results include:

RESPIRATORY SUPPORT

            1)  Ipratropium bromide (Atrovent) inhaler treatment every 4-hours.

            Inhalers 2-puffs every 4 hours. Nebulizer 500 mcg every 4 hours (adults).             Dose to be reduced accordingly for children.

THROMBOSIS REDUCTION

1) Either heparin 5000 units subcutaneously every 12 hours OR Enoxaparin 1mg/kg body weight subcutaneously every 12 hours. AND

2) Aspirin 325 mg tablets (once or twice daily as tolerated),

3) Equivalent given specifics of person.

IMMUNE SUPPORT

1) Folate (B9) 3 mg by mouth daily

2) Magnesium 400 mg by mouth daily

3) Calcium Carbonate 400 mg by mouth daily

4) Cobalamin (B12) 3 mg by mouth daily

5) Pyridoxine (B6) 30 mg by mouth daily

6) Dehydroepiandrosterone (DHEA) 50 mg by mouth twice daily

7) Ascorbic acid (C) 2000 mg by mouth daily

8) Zinc 10 mg by mouth daily, and

9) 1,25-dihydroxycholecalciferol (D3) 1500 IU by mouth daily

 

Based upon best available evidence research results, viruses have been treated by focusing on viral attachment and replication. Given the InflammoThrombotic Response (ITR) to SARS-CoV-2, and the best available evidence research results, patients infected with the virus with adverse outcomes are developing ITRs. Currently suggested treatments based upon best available evidence research results include the following.

 

CURRENTLY SUGGESTED TREATMENTS BASED UPON BEST AVAILABLE EVIDENCE RESEARCH RESULTS FOR PEOPLE INFECTED BY SARS-CoV-2 WHO ARE NOT HOSPITALIZED

 

 

CURRENTLY SUGGESTED TREATMENTS BASED UPON BEST AVAILABLE EVIDENCE RESEARCH RESULTS FOR PEOPLE INFECTED BY SARS-CoV-2 WHO ARE HOSPITALIZED WITH COVID-19 (ITR to Virus)

 

 

CURRENTLY SUGGESTED TREATMENTS BASED UPON BEST AVAILABLE EVIDENCE RESEARCH RESULTS FROM PHYSICIANS REPORTING CLINICALLY SUCCESSFUL TREATMENTS

 

CURRENT POTENTIAL TREATMENTS CONSIDERATIONS BASED UPON BEST AVAILABLE EVIDENCE RESEARCH RESULTS - FOCUSING ON SPECIFIC COMPONENTS - FOR PEOPLE WHO HAVE BEEN VACCINATED

 

Based upon the best available evidence currently being collected, the fundamental goals for treating potential complications from drug vaccine delivery of genetic material, includes first blocking the Nuclear Protein Complex (NPC), to minimize continued entry and re-entry of this genetic material into the cellular nuclear region where reverse transcription (RT) could occur; protecting the native human DNA.

The next step is to remove any circulation spike proteins, minimizing the potential harm they might cause including InflammoThrombotic Response (ITR) disease and Prion diseases. The next logical step would be to interfere with any reuptake of spike protein by host cells that could serve as potential new sources of prions, mRNA or DNA, with potential RT, or any other potential sources of SARS-CoV-2 genetic material or any other genetic or non-genetic material circulating from the injected drug vaccines.

The fourth goal is to minimize any potential damage caused by the prion-like domains (PLDs) including reducing the potential longer term neurologic, cardiac, and other organ tissue damage.

This sequence of steps will hopefully reduce the genetic load introduced into the body by these drug vaccines. By interfering with the entry and re-entry of this genetic material through the NPC through this series of steps, this will hopefully provide adequate time for sufficient glycosylase enzyme removal of genetic bases or nucleotide excision - repair mechanisms - of any damaged DNA; through continued encouragement of transcription of the viral – and other – genetic material, increasing the potential for these DNA repairs to occur.

In essence, by reducing the active viral or spike protein load through these steps, the increased transcription required for maintenance of the genetic code or protein products, will increase the potential for DNA excision repair and exhaust or at a minimum fatigue the viral genetic load.

Step 1: Stop the Reverse Transcriptase (RT) – Block the Nuclear Protein Complex (NPC)

             (A)   Ivermectin 0.2-0.4 mg/kg body weight by mouth (PO) every two weeks.

 Step 2: Remove Spike Protein in circulation that could cause ITR or prion-like initiated amyloid or equivalent plaquing.

             (A)   Casirivimab 1200 mg & Imdevimab 1200 mg provided intravenously together as a single                 infusion over a minimum of 60-minutes.

 Step 3A: Reduce further uptake of Spike protein by cells throughout the body including transmission across the Blood Brain Barrier (BBB).

             (A) Primaquine 200 mg orally given once – Targets ACE2 receptor.

 (B) Clindamycin 150 mg orally every 6-hours for 7-days – Targets transmembrane protease                         serine 2 (TMPRSS2) receptor.

 (C) Hydroxychloroquine 200 mg orally twice a week – Targets ACE2 receptor.

Step 3B: Reduce further translation of mRNA to spike protein.

(A) The Primaquine from 3A also inhibits viral protein translation (production of spike protein         from mRNA).

(B)   The Clindamycin from 3A also inhibits viral protein translation; reduces ITR by reducing                     tissue necrosis factor – alpha (TNF-α) and interleukin-1 beta (IL1β).

(C) The Hydroxychloroquine from 3A enhances zinc entry through the zinc ionophore;                                 enhances the production of type 1 interferons, interferes with ribosomal translation of the                      spike protein, reduces interleukin-6 (IL-6) levels; 5 June 2021 9 increases cellular pH                             thereby decreasing viral antigen (mRNA or spike protein) major histocompatability                                 complex (MHC) presentation of the spike protein to Β-cells reducing antibody formation                      and ITR.

 (D) Zinc 10 mg orally (po) daily. While this may also interfere with the ACE2 receptor, it also                     interferes with RNA dependent RNA polymerase (RdRP).

 (E) Ascorbic Acid (Vitamin C) 2000 mg orally (po) daily to reduce ITR.

 (F) 1,25-dihydroxycholecalciferol (Vitamin D3) 1500 IU orally (po) daily to reduce ITR.

 Step 4: Address potential amyloid production and neurologic sequlae resulting from prion-like domains on spike protein. 

             (A) Either heparin 5000 units subcutaneously every 12 hours OR Enoxaparin 1mg/kg body                             weight subcutaneously every 12 hours. AND

 (B) Aspirin 325 mg tablets (once or twice daily as tolerated),

 (C) Treat ApoE through dietary and lifestyle factors; HMG CoA-reductase inhibitors or                 Probucol [An ATP-binding transporter A1 (ABCA1)].

 (C)   Niacin (Vitamin B3) 15 mg twice daily.

 

 

 

 2. No Symptoms

 

 3. Phase I Mild Symptoms

 

 

 4. Outpatient SARS-CoV-2 Infection

 

 5. Inpatient InflammoThrombotic Response (ITR) COVID-19

 6. Combined Outpatient Infection & Inpatient COVID-19 (costs)

 

 

 7. Combined Outpatient Infection & Inpatient COVID-19

 

 

9.  Vaccine Adverse Events & Shedding

 

© 2021 by Richard M. Fleming, PhD, MD, JD  All rights reserved.